Phase 2 Multiple Sclerosis Trial, Not Yet Recruiting NCT06961383 Sponsor: NeuroGenesis Ltd. Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Phase 2 Multiple Sclerosis Trial, Not Yet Recruiting

NCT06961383
Not Yet Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People aged 18 to 65 years old.
  • People who have been diagnosed with secondary progressive multiple sclerosis (SPMS).
  • People whose disability has been documented as worsening over the 2 years before joining the study — either by a certain amount on a standard disability scale (EDSS), or by at least a 20% slowdown on a timed walking test (T25FW); if these records are not available, a written clinical summary may be submitted for review by a special committee (confirm with trial site).
  • People whose disability score (EDSS) falls between 3.5 and 6.5 at the screening visit.
  • People whose timed 25-foot walk test (T25FW) result is between 8.0 and 25 seconds at the screening visit.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have had a documented MS relapse in the 24 months before enrolling, or who show signs of active lesions on an MRI taken at screening.
  • People who are pregnant, breastfeeding, or who are able to become pregnant and are not using an acceptable form of contraception.
  • People who have a history of another long-term, disabling condition other than MS.
  • People who have a clotting disorder.
  • People who are unable to have an MRI scan.
  • People who have uncontrolled liver, kidney, or heart disease, or who have cancer.
  • People whose laboratory test results are outside the normal range in a way the investigator considers medically significant.
  • People with a history of, or current, alcohol abuse or drug addiction.
  • People with untreated or uncontrolled mental health conditions, or who are assessed as having a risk of suicide based on a standard rating scale (C-SSRS).
  • People who have taken part in another research study involving an investigational treatment in the 90 days before joining, or who plan to use another investigational treatment during the study.
  • People who have previously received the treatment being studied (NG01/MSCs).
  • People who, in the investigator's opinion, may not be able to fully understand the consent process, are unlikely to follow the study procedures, or for whom long-term follow-up may be difficult.
  • People who experience a relapse between the screening visit and the point of being assigned to a treatment group (randomisation).
  • People who have been on their current MS disease-modifying therapy for less than 6 months.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026

If you need support right now

This page includes language about suicide and self-harm, because that is how the trial's eligibility criteria are written. If reading it has been hard, you do not have to keep going. The services below are free, confidential, and answered by people trained for exactly this.

If you or someone else is in immediate danger, call 000.

  • Lifeline — 24/7 crisis support: 13 11 14
  • Suicide Call Back Service — 24/7 counselling: 1300 659 467
  • 13YARN — 24/7, for Aboriginal and Torres Strait Islander people: 13 92 76
  • Beyond Blue — 24/7 mental health support: 1300 22 4636
  • Emergency: 000

Outside Australia? The numbers above are Australian and will not work from overseas. Find a Helpline is a free directory of crisis lines in over 130 countries, run by ThroughLine with the International Association for Suicide Prevention. If you are in immediate danger, call your local emergency number.

Voxsanity is not a crisis service, and nothing on this page is medical advice. More Australian services are listed on our support lines page.

Contact this trial

Phone: 305-243-4015

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
NeuroGenesis Ltd.
Registry
ClinicalTrials.gov
Start date
1 October 2025
Est. completion
1 October 2027

Where this trial is recruiting

🇮🇱 Israel 🇺🇸 United States

Primary endpoints

Walking Ability; Incidence of Treatment-Emergent Adverse Events (AEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov